Literature DB >> 23904763

Impact of the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology clinical practice guidelines for EGFR and ALK testing in lung cancer in Canada.

D N Ionescu.   

Abstract

This paper summarizes the practical impact of the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology lung cancer biomarkers guidelines on the lung cancer approach in Canada, providing possible practical solutions for other similar health care systems in which scientific reality needs to be constantly balanced against economic reality.

Entities:  

Keywords:  Association for Molecular Pathology; College of American Pathologists; International Association for the Study of Lung Cancer; Lung cancer; amp; cap; guidelines; iaslc

Year:  2013        PMID: 23904763      PMCID: PMC3728053          DOI: 10.3747/co.20.1568

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  30 in total

Review 1.  Microdissection techniques for molecular testing in surgical pathology.

Authors:  Jennifer L Hunt; Sydney D Finkelstein
Journal:  Arch Pathol Lab Med       Date:  2004-12       Impact factor: 5.534

Review 2.  A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.

Authors:  Peter M Ellis; Normand Blais; Dennis Soulieres; Diana N Ionescu; Meenakshi Kashyap; Geoff Liu; Barb Melosky; Tony Reiman; Phillippe Romeo; Frances A Shepherd; Ming-Sound Tsao; Natasha B Leighl
Journal:  J Thorac Oncol       Date:  2011-08       Impact factor: 15.609

3.  Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.

Authors:  Natasha Rekhtman; Suzanne M Brandt; Carlie S Sigel; Maria A Friedlander; Gregory J Riely; William D Travis; Maureen F Zakowski; Andre L Moreira
Journal:  J Thorac Oncol       Date:  2011-03       Impact factor: 15.609

Review 4.  Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing.

Authors:  William D Travis; Natasha Rekhtman
Journal:  Semin Respir Crit Care Med       Date:  2011-04-15       Impact factor: 3.119

5.  Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.

Authors:  Marissa N Balak; Yixuan Gong; Gregory J Riely; Romel Somwar; Allan R Li; Maureen F Zakowski; Anne Chiang; Guangli Yang; Ouathek Ouerfelli; Mark G Kris; Marc Ladanyi; Vincent A Miller; William Pao
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

Review 6.  Molecular diagnostics of lung carcinomas.

Authors:  Sanja Dacic
Journal:  Arch Pathol Lab Med       Date:  2011-05       Impact factor: 5.534

7.  The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

Authors:  Daisy Wing-Sze Wong; Elaine Lai-Han Leung; Kimpton Kam-Ting So; Issan Yee-San Tam; Alan Dart-Loon Sihoe; Lik-Cheung Cheng; Kwok-Keung Ho; Joseph Siu-Kie Au; Lap-Ping Chung; Maria Pik Wong
Journal:  Cancer       Date:  2009-04-15       Impact factor: 6.860

8.  The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers.

Authors:  A J Atherly; D R Camidge
Journal:  Br J Cancer       Date:  2012-02-28       Impact factor: 7.640

9.  Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.

Authors:  Heidi Greulich; Tzu-Hsiu Chen; Whei Feng; Pasi A Jänne; James V Alvarez; Mauro Zappaterra; Sara E Bulmer; David A Frank; William C Hahn; William R Sellers; Matthew Meyerson
Journal:  PLoS Med       Date:  2005-10-04       Impact factor: 11.069

10.  BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

Authors:  Daniel B Costa; Balázs Halmos; Amit Kumar; Susan T Schumer; Mark S Huberman; Titus J Boggon; Daniel G Tenen; Susumu Kobayashi
Journal:  PLoS Med       Date:  2007-10       Impact factor: 11.069

View more
  6 in total

1.  Ready or not? Lung cancer diagnosis in 2015.

Authors:  K Jao; C Labbe; N B Leighl
Journal:  Curr Oncol       Date:  2015-08       Impact factor: 3.677

2.  Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario.

Authors:  C Lim; H S Sekhon; J C Cutz; D M Hwang; S Kamel-Reid; R F Carter; G da Cunha Santos; T Waddell; M Binnie; M Patel; N Paul; T Chung; A Brade; R El-Maraghi; C Sit; M S Tsao; N B Leighl
Journal:  Curr Oncol       Date:  2017-04-27       Impact factor: 3.677

Review 3.  Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

Authors:  B Melosky; P Cheema; J Agulnik; R Albadine; D G Bebb; N Blais; R Burkes; C Butts; P B Card; A M Y Chan; V Hirsh; D N Ionescu; R Juergens; W Morzycki; Z Poonja; R Sangha; M Tehfe; M S Tsao; M Vincent; Z Xu; G Liu
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

4.  Validity of Natural Language Processing for Ascertainment of EGFR and ALK Test Results in SEER Cases of Stage IV Non-Small-Cell Lung Cancer.

Authors:  Bernardo Haddock Lobo Goulart; Emily T Silgard; Christina S Baik; Aasthaa Bansal; Qin Sun; Eric B Durbin; Isaac Hands; Darshil Shah; Susanne M Arnold; Scott D Ramsey; Ramakanth Kavuluru; Stephen M Schwartz
Journal:  JCO Clin Cancer Inform       Date:  2019-05

5.  Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

Authors:  B Melosky; J Agulnik; R Albadine; S Banerji; D G Bebb; D Bethune; N Blais; C Butts; P Cheema; P Cheung; V Cohen; J Deschenes; D N Ionescu; R Juergens; S Kamel-Reid; S A Laurie; G Liu; W Morzycki; M S Tsao; Z Xu; V Hirsh
Journal:  Curr Oncol       Date:  2016-06-09       Impact factor: 3.677

6.  Standardizing biomarker testing for Canadian patients with advanced lung cancer.

Authors:  B Melosky; N Blais; P Cheema; C Couture; R Juergens; S Kamel-Reid; M-S Tsao; P Wheatley-Price; Z Xu; D N Ionescu
Journal:  Curr Oncol       Date:  2018-02-28       Impact factor: 3.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.